- InspireMD (NASDAQ: NSPR) reported better-than-expected Q2 earnings, with a narrower loss per share of -$0.17 and revenue of $1.77 million, surpassing analyst estimates.
- The company achieved robust international market growth of 21% for its CGuard platform, which significantly contributed to its financial performance.
- Despite a voluntary U.S. product recall, InspireMD is strategically preparing for the future U.S. re-launch of its CGuard platform, including a key executive appointment to bolster its market presence.
InspireMD, Inc. (NASDAQ: NSPR) is a medical device company that operates within the medical instruments industry. The company focuses on developing and marketing its CGuard platform. This platform is a carotid stent system specifically designed to help prevent strokes in patients being treated for carotid artery disease.
On August 17, 2026, InspireMD reports its second-quarter earnings results. The company announces a loss per share of -$0.17, which is better than the analyst consensus estimate of a -$0.20 loss. As highlighted by Zacks, this marks a 15.00% earnings surprise and an improvement from the -$0.26 loss per share from one year ago.
The company also posts quarterly revenue of $1.77 million, surpassing the analyst estimate of $1.38 million. This performance is supported by strong international market growth of 21% for its key products across several countries.
This robust international growth helps to offset the financial impact of a voluntary product recall in the U.S. The recall, which occurred in May, affected the CGuard Prime 135 cm delivery system. In response, InspireMD has identified and is implementing design changes to the system.
In a strategic move, InspireMD prepares for the future U.S. re-launch of its CGuard platform. To support this goal, the company appoints Kathleen Kennedy as its new Senior Vice President of Global Sales and Marketing. This appointment signals a focus on rebuilding its U.S. market presence.
